A collapse of genome integrity caused by the cumulative effects of PARP inhibition and defective homologous recombination (HR) repair kills BRCA-deficient tumor cells, whereas cells with intact HR repair are largely unaffected by PARP inhibitors under normal conditions. The gene discussed is PARP1; the disease is neoplasm.